← Patent-cliff monitor Loss of exclusivity September 2033 latest FDA-listed patent expiry
Drug detail Brand name VANFLYTA Active ingredient QUIZARTINIB DIHYDROCHLORIDE Strength EQ 26.5MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2023 Marketing status RX
Listed patents Patent Expires Type 9675549 September 2033 product 8357690 February 2031 use U-3661 9555040 May 2030 use U-3661 8836218 March 2030 use U-3661 7968543 August 2029 product 8865710 August 2029 product 7820657 September 2028 substance 8557810 March 2027 product 8129374 March 2027 use U-3661 8883783 March 2027 substance 9585892 March 2027 use U-3661
Regulatory exclusivity Code Expires ODE-437 July 2030 NCE July 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.